"
Team:METU-Gene/Collagen Sponge
From 2009.igem.org
(→The release rate of bioactive hEGF from crosslinking collagen sponges ==) |
(→The release rate of bioactive hEGF from crosslinking collagen sponges ==) |
||
| Line 15: | Line 15: | ||
conditions. | conditions. | ||
| - | <br> | + | <br>A good correlation was obtained for |
in vitro release rates of rhEGF using the power model. The | in vitro release rates of rhEGF using the power model. The | ||
crosslinked rhEGF collagen sponges showed a successful | crosslinked rhEGF collagen sponges showed a successful | ||
| Line 36: | Line 36: | ||
concentration at the wound site for a certain period of time | concentration at the wound site for a certain period of time | ||
has become vital in the application of EGF. Indeed, we increased this continuous exposures by using Quaroum Sensing Mechanism of E.coli. | has become vital in the application of EGF. Indeed, we increased this continuous exposures by using Quaroum Sensing Mechanism of E.coli. | ||
| + | |||
| + | |||
| + | <br>Collagen is a major constituent of the connective tissue | ||
| + | and is potentially a highly useful biomaterial. It has characteristics | ||
| + | that are suitable in medical application, such as | ||
| + | '''biodegradability''' and weak antigenicity, and it has been | ||
| + | used in resorbable surgical sutures, hemostatic agents, and | ||
| + | wound dressings for many years. | ||
Revision as of 10:32, 13 October 2009
The release rate of bioactive hEGF from crosslinking collagen sponges ==
The purpose of this study was to prepare
recombinant human epidermal growth factor (rhEGF)
collagen sponges for topical applications and investigate
the effects of different types of crosslinked collagen
sponges as platforms for the controlled release of rhEGF.
The microstructure and the drug release rates of collagen
sponges were modified through treatment with different
types (glutaraldehyde (GTA), genipin and 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC)), different
concentrations of crosslinking agents and various preparation
conditions.
A good correlation was obtained for
in vitro release rates of rhEGF using the power model. The
crosslinked rhEGF collagen sponges showed a successful
delivery of rhEGF in bioactive form to stimulate cell
proliferation.
In addition, EGF can inhibit gastric
acid secretions in the stomach, enhance the proliferation
and keratinization of epithelial tissues and
accelerate wound healing. Due to its wound healing
properties, EGF is an attractive candidate for a therapeutic
drug. Studies have demonstrated that topical applications
of EGF promote wound healing in healthy and impaired
healing animals.
Since Carpenter and co-workers
first reported that for a mitogenic effect of EGF, a continuous
exposure of the target cells to EGF was required for
a minimum of 6–12 h, maintaining an effective topical
concentration at the wound site for a certain period of time
has become vital in the application of EGF. Indeed, we increased this continuous exposures by using Quaroum Sensing Mechanism of E.coli.
Collagen is a major constituent of the connective tissue
and is potentially a highly useful biomaterial. It has characteristics
that are suitable in medical application, such as
biodegradability and weak antigenicity, and it has been
used in resorbable surgical sutures, hemostatic agents, and
wound dressings for many years.
